GSKADC therapy Phase 3 clinical results are positive, extending the lives of patients with refractory cancer
GSK announced today that its antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin) achieved positive results in the pre-specified interim analysis of the Phase 3 clinical trial DREAMM-7. The trial evaluated the efficacy of Blenrep in combination with bortezomib and dexamethasone (BorDex) as a second-line or later treatment for relapsed or refractory multiple myeloma. The trial met the key secondary endpoint of overall survival (OS), demonstrating that Blenrep combined with BorDex significantly reduced the risk of death for patients compared to standard treatment regimens. The interim analysis results, including safety data, will be presented at the upcoming 66th American Society of Hematology (ASH) Annual Meeting. Blenrep is a targeted antibody-drug conjugate that targets B-cell maturation antigen (BCMA), consisting of a humanized anti-BCMA monoclonal antibody linked to the cytotoxic payload auristatin F via an indelible linker
According to Zhitong Finance APP, GSK (GSK.US) announced today that its antibody-drug conjugate (ADC) Blenrep (belantamab mafodotin) achieved positive results in the pre-specified interim analysis of the Phase 3 clinical trial DREAMM-7. The trial evaluated the efficacy of Blenrep in combination with bortezomib and dexamethasone (BorDex) as a second-line or later treatment for relapsed or refractory multiple myeloma. The trial met the key secondary endpoint of overall survival (OS), showing that Blenrep combined with BorDex significantly reduced the risk of death for patients compared to standard treatment regimens. The interim analysis results, including safety data, will be presented at the upcoming 66th American Society of Hematology (ASH) Annual Meeting.
Blenrep is a targeted antibody-drug conjugate that targets B-cell maturation antigen (BCMA), composed of a humanized anti-BCMA monoclonal antibody linked to the cytotoxic payload auristatin F via an indelible linker
